	US 12,257,343 B2
	Excipients to reduce the viscosity of antibody formulations and formulation compositions
Jian Hua Gu, Thousand Oaks, CA (US); Robert Matthew Fesinmeyer, Newbury Park, CA (US); and Rulin Qian, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 16/609,448
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Apr. 24, 2018, PCT No. PCT/US2018/029156 § 371(c)(1), (2) Date Oct. 29, 2019, PCT Pub. No. WO2018/200533, PCT Pub. Date Nov. 1, 2018.
Claims priority of provisional application 62/492,049, filed on Apr. 28, 2017.
Prior Publication US 2020/0352857 A1, Nov. 12, 2020
Int. Cl. A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 47/18 (2017.01); C07K 16/24 (2006.01); C07K 16/40 (2006.01)

CPC A61K 9/08 (2013.01) [A61K 9/19 (2013.01); A61K 47/183 (2013.01); C07K 16/244 (2013.01); C07K 16/40 (2013.01)]

15 Claims

1. A liquid pharmaceutical formulation comprising an antibody, a buffer, and at least one oligopeptide selected from Arg-Lys, Arg-Phe, Arg-Pro, Arg-Val, Arg-Ala, Asp-Arg, Lys-Arg, Pro-Arg, Leu-Arg, Val-Arg, Phe-Arg, Arg-Tyr, and Ala-Arg, (ii) the buffer is acetate, glutamate, or phosphate and (iii) the pH of the formulation is from about 4.5 to about 6.5, wherein the formulation has a viscosity of no more than 40 cP at 25° C.